Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Why Vericel Shares Will Double In 2015

On January 15, 2015, we had a chance to sit down for a face-to-face meeting with the senior management team at Vericel Corporation (VCEL). At the meeting, management laid out their plans for generating growth and driving profitability at the Cell Therapy and Regenerative Medicine (CTRM) business newly acquired from Sanofi in 2014. We were also provided with a brief update on the status of the Phase 2b ixCELL-DCM study with ixmyelocel-T for the treatment of ischemic dilated cardiomyopathy. Below we outline some of the key strategies and initiatives that management has planned for 2015 and conclude with our thoughts on why we believe investment in Vericel Corp. makes sense at this level.

Third Quarter Financials Provide a Glimpse Into The Future

On November 13, 2014, Vericel reported financial results for the quarter ending September 30, 2014. This was the first full quarter of operations for the company's recently acquired… Read More …